Program
Beclomethasone
Also written as “Beclomethasone dipropionate”, “Beclometasone/Formoterol/Glycopyrrolate” and “beclomethasone”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, Perennial · Graft vs Host Disease, led by 7 companies.
Drug pageBeclomethasone: every studyMany companies study it; this page follows only the 44 they lead. All 85 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chiesi Farmaceuticiits history only | 220 open or running | phase 4since Oct 28, 2020 | Sep 29, 2006 | none ahead |
| Teva Pharmaceutical Industriesits history only | 140 open or running | phase 4since Oct 28, 2003 | Oct 28, 2003 | none ahead |
| Soligenixits history only | 30 open or running | phase 3since Jun 19, 2009 | Jun 19, 2009 | none ahead |
| Adamis Pharmaceuticalsits history only | 20 open or running | phase 3since Feb 6, 2019 | Feb 6, 2019 | none ahead |
| Enteron Pharmaceuticalsits history only | 10 open or running | phase 3since Oct 4, 2005 | Oct 4, 2005 | none ahead |
| Lunan Pharmaceutical Groupits history only | 11 open or running | phase 3since Jul 21, 2026 | Jul 21, 2026 | Jun 2028phase 3 · NCT07768891 |
| SOFARits history only | 10 open or running | phase 1since Apr 26, 2021 | Apr 26, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 27 studies since Oct 28, 2003.
- Aug 16, 2013Phase 2 study in Chronic Gastrointestinal Graft vs Host DiseaseSoligenix · NCT01925950 · 2 enrolled · United States
- Jan 7, 20143 phase 3 studies in AsthmaTeva Pharmaceutical Industries · NCT02031640, NCT02040779, NCT02040766
- Jan 9, 2014Phase 1 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT02040597 · 42 enrolled · Poland
- Apr 11, 2014Phase 1 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT02119234 · 36 enrolled · Poland
- May 21, 2014Phase 2 study in AsthmaChiesi Farmaceutici · NCT02148120 · 60 enrolled · United Kingdom
- Nov 15, 2016Phase 1 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT02975843 · 28 enrolled
- Aug 23, 2017Phase 3 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT03268226 · 20 enrolled · Belgium, Hungary
- Feb 6, 2019Adamis Pharmaceuticals’ first studies: 2 phase 3 studies in AsthmaNew to Adamis PharmaceuticalsAdamis Pharmaceuticals · NCT03834012, NCT03835871
- Oct 28, 2020Phase 4 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT04671355
- Apr 26, 2021SOFAR’s first study: phase 1 study in Healthy Adult Male VolunteersNew to SOFARSOFAR · NCT04873063 · 28 enrolled · Italy
- Apr 27, 2021Phase 3 study in AsthmaChiesi Farmaceutici · NCT04886999 · 78 enrolled · Italy
- May 3, 2021Phase 3 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT04876677 · 25 enrolled · Belgium, Hungary
- Mar 4, 2022Phase 3 study in AsthmaChiesi Farmaceutici · NCT05292586 · 1,377 enrolled · United States
- Jul 21, 2026Lunan Pharmaceutical Group’s first study: phase 3 study in AsthmaNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT07768891 · 416 planned · China
Ahead
- Jun 2028Primary completion: phase 3 study in AsthmaLunan Pharmaceutical Group · NCT07768891
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
All 44 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07768891Asthma · China | 3 | Recruiting | Lunan Pharmaceutical Group | Jun 2028 | 416 |
| NCT05292586Asthma · United States | 3 | Completed | Chiesi Farmaceutici | Jun 24, 2024 | 1,377 |
| NCT04876677Pulmonary Disease, Chronic Obstructive · Belgium, Hungary | 3 | Completed | Chiesi Farmaceutici | Jan 3, 2022 | 25 |
| NCT04886999Asthma · Italy | 3 | Completed | Chiesi Farmaceutici | Feb 1, 2023 | 78 |
| NCT04873063Healthy Adult Male Volunteers · Italy | 1 | Completed | SOFAR | Apr 28, 2022 | 28 |
| NCT04671355Pulmonary Disease, Chronic Obstructive | 4 | Withdrawn | Chiesi Farmaceutici | Dec 22, 2021 | 0 |
| NCT03835871Asthma | 3 | Withdrawn | Adamis Pharmaceuticals | Dec 2019 | 0 |
| NCT03834012Asthma | 3 | Withdrawn | Adamis Pharmaceuticals | Nov 2019 | 0 |
| NCT03268226Pulmonary Disease, Chronic Obstructive · Belgium, Hungary | 3 | Completed | Chiesi Farmaceutici | Jan 30, 2019 | 20 |
| NCT02975843Pulmonary Disease, Chronic Obstructive | 1 | Completed | Chiesi Farmaceutici | Mar 21, 2017 | 28 |
| NCT02148120Asthma · United Kingdom | 2 | Completed | Chiesi Farmaceutici | Oct 2014 | 60 |
| NCT02119234Pulmonary Disease, Chronic Obstructive · Poland | 1 | Completed | Chiesi Farmaceutici | Feb 2015 | 36 |
| NCT02040779Asthma · United States | 3 | Completed | Teva Pharmaceutical Industries | Dec 24, 2014 | 273 |
| NCT02040766Asthma · United States, Croatia, Mexico and more | 3 | Completed | Teva Pharmaceutical Industries | Feb 2016 | 628 |
| NCT02040597Pulmonary Disease, Chronic Obstructive · Poland | 1 | Completed | Chiesi Farmaceutici | Apr 2015 | 42 |
| NCT02031640Asthma · United States, Germany, Hungary and more | 3 | Completed | Teva Pharmaceutical Industries | Nov 2014 | 1,113 |
| NCT01925950Chronic Gastrointestinal Graft vs Host Disease · United States | 2 | Terminated | Soligenix | May 2015 | 2 |
| NCT01917331Pulmonary Disease, Chronic Obstructive · Hungary | 3 | Completed | Chiesi Farmaceutici | Jan 14, 2016 | 1,368 |
| NCT01783548Rhinitis, Allergic · United States | 3 | Completed | Teva Pharmaceutical Industries | Oct 2013 | 547 |
| NCT01803087Asthma · Poland | 2 | Completed | Chiesi Farmaceutici | Oct 2012 | 60 |
| NCT01658891Asthma in Children · Denmark | 3 | Withdrawn | Chiesi Farmaceutici | Nov 2015 | 0 |
| NCT01691677Acute Rhinosinusitis · Italy | 3 | Completed | Chiesi Farmaceutici | Jan 2014 | 166 |
| NCT01584492Asthma · Poland, Ukraine | 2 | Completed | Chiesi Farmaceutici | Feb 2013 | 59 |
| NCT01475032Asthma · Bulgaria, France, Germany and more | 3 | Completed | Chiesi Farmaceutici | Sep 2012 | 638 |
| NCT01307319Rhinitis, Allergic, Seasonal · United States | 3 | Completed | Teva Pharmaceutical Industries | Jul 2011 | 715 |
| NCT01134705Rhinitis, Allergic, Perennial · United States | 3 | Completed | Teva Pharmaceutical Industries | Oct 2010 | 474 |
| NCT01133626Rhinitis, Allergic, Perennial · United States | 3 | Completed | Teva Pharmaceutical Industries | Sep 2010 | 107 |
| NCT01073384Enteritis · United States | 2 | Completed | Soligenix | Jan 2012 | 16 |
| NCT01024608Rhinitis, Allergic, Seasonal · United States | 3 | Completed | Teva Pharmaceutical Industries | Feb 28, 2010 | 340 |
| NCT00988247Rhinitis, Allergic, Perennial · United States | 3 | Completed | Teva Pharmaceutical Industries | Feb 28, 2011 | 529 |
| NCT00926575Acute Gastrointestinal Graft vs Host Disease · United States | 3 | Terminated | Soligenix | Dec 2011 | 140 |
| NCT00861926Asthma · Bulgaria, Croatia, Czechia and more | 3 | Completed | Chiesi Farmaceutici | Dec 7, 2010 | 1,714 |
| NCT00854360Rhinitis, Allergic, Seasonal · United States | 2 | Completed | Teva Pharmaceutical Industries | May 2009 | 487 |
| NCT00497523Asthma · Poland, Ukraine | 3 | Completed | Chiesi Farmaceutici | 283 | |
| NCT00497237Asthma · Bulgaria, Italy, Ukraine | 3 | Completed | Chiesi Farmaceutici | Mar 2010 | 382 |
| NCT00476268Asthma | 3 | Completed | Chiesi Farmaceutici | Jan 2005 | 824 |
| NCT00413387Asthma · Austria, Poland, Ukraine | 3 | Completed | Chiesi Farmaceutici | Aug 2005 | 219 |
| NCT00394368Asthma · Poland, Ukraine | 3 | Completed | Chiesi Farmaceutici | 180 | |
| NCT00382889Asthma · Austria, Italy, Poland and more | 3 | Completed | Chiesi Farmaceutici | 480 | |
| NCT00250341Asthma · United States | 4 | Completed | Teva Pharmaceutical Industries | Sep 30, 2007 | 34 |
| NCT00233896Graft vs Host Disease · United States | 3 | Completed | Enteron Pharmaceuticals | 130 | |
| NCT00109668Asthma · United States, Puerto Rico | 3 | Completed | Teva Pharmaceutical Industries | Sep 30, 2006 | 415 |
| NCT00094016Asthma · United States, Puerto Rico | 3 | Completed | Teva Pharmaceutical Industries | Jun 30, 2006 | 440 |
| NCT00071552Asthma · United States | 4 | Terminated | Teva Pharmaceutical Industries | Jul 31, 2006 | 49 |
How it is read
Names in the registry
- “Beclomethasone dipropionate”, 6 entries
- “Beclometasone/Formoterol/Glycopyrrolate”, 2 entries
- “beclomethasone”, 2 entries
- “beclomethasone dipropionate plus formoterol fumarate combination”, 2 entries
- “Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium”, 2 entries
Conditions, from the studies’ own filings
- Asthma, 25 studies
- Pulmonary Disease, Chronic Obstructive, 7 studies
- Rhinitis, Allergic, Seasonal, 3 studies
- Rhinitis, Allergic, Perennial, 3 studies
- Graft vs Host Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.